AbbVie Announces Leadership Team and
Creation of New Business, Allergan Aesthetics, Upon Completion of
Acquisition
NORTH CHICAGO, Illinois,
Jan. 8, 2020 -- AbbVie (NYSE: ABBV),
a research-based global biopharmaceutical company, today announced
the creation of a new global business, Allergan Aesthetics, an
AbbVie company, and the proposed leadership team for the combined
company, effective upon the expected first-quarter 2020 close of
the Allergan acquisition.
Allergan Aesthetics will operate as a new global dedicated
business with its own research and development function under the
AbbVie umbrella and will include leading aesthetic products
including, BOTOX Cosmetic, the JUVEDERM collection of dermal
fillers and COOLSCULPTING body contouring, among others. This
global business, located in Irvine,
California, will be led by Carrie
Strom, currently Senior Vice President, U.S. Medical
Aesthetics, Allergan. Upon completion of the Allergan acquisition,
Ms. Strom will be named Senior Vice President, AbbVie and
President, Global Allergan Aesthetics. She will oversee the
worldwide operations, along with an experienced team of current
Allergan leaders, and report directly to Richard A. Gonzalez, Chairman and Chief
Executive Officer, AbbVie.
The Eye Care and Specialty businesses – including BOTOX
Therapeutics, Central Nervous System, Women's Health and
Gastrointestinal Diseases – will be integrated into the existing
AbbVie organization. Several Allergan leaders have accepted
leadership positions in the future company across these
franchises.
The following individuals will make up the Executive Leadership
team of the combined company:
-
Richard A. Gonzalez, Chairman and
Chief Executive Officer
-
Laura Schumacher, Vice Chairman,
External Affairs and Chief Legal Officer
-
Michael E. Severino, M.D., Vice
Chairman and President (including Research and Development)
-
Carlos Alban, Vice Chairman,
Chief Commercial Officer
-
Henry O. Gosebruch, Executive
Vice President, Chief Strategy Officer
-
Robert A. Michael, Executive Vice
President, Chief Financial Officer
-
Timothy J. Richmond, Executive
Vice President, Chief Human Resources Officer
-
Azita Saleki-Gerhardt, Ph.D.,
Executive Vice President, Operations
- Carrie Strom, Senior Vice
President, AbbVie, and President, Global Allergan Aesthetics
"We are enthusiastic about the potential of the new AbbVie and
continue to make significant progress on completing our acquisition
of Allergan," said Richard A.
Gonzalez, chairman and chief executive officer, AbbVie.
"Today's announcement marks an important step forward in our plans
to create the integrated global company. We are fortunate to
have a leadership team with a deep breadth of both industry and
company experience and we are excited to welcome the new Allergan
leaders to our Company."
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company
committed to developing innovative advanced therapies for some of
the world's most complex and critical conditions. The company's
mission is to use its expertise, dedicated people and unique
approach to innovation to markedly improve treatments across four
primary therapeutic areas: immunology, oncology, virology and
neuroscience. In more than 75 countries, AbbVie employees are
working every day to advance health solutions for people around the
world. For more information about AbbVie, please visit us at
www.abbvie.com. Follow @abbvie on Twitter or view careers on our
Facebook or LinkedIn page.
The Directors of AbbVie Inc. accept
responsibility for the information contained in this announcement.
To the best of their knowledge and belief (having taken all
reasonable care to ensure such is the case), the information
contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such
information.
Any holder of 1% or more of any class
of relevant securities of AbbVie Inc. may have disclosure
obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997,
Takeover Rules 2013.
CONTACT: Media: Adelle Infante, (847) 938-8745, Investors:
Liz Shea, (847) 935-2211